StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) company profile

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$72.00−0.68 (-0.94%)

Close on Nov 13, 2026Market cap $483.28MP/E –Yield –

About Monopar Therapeutics

Pharmaceutical Preparations, SIC 2834

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Wilson disease and targeted radiopharmaceuticals for oncology. Its primary therapeutic asset is ALXN1840, an investigational oral small molecule designed to bind and remove copper in Wilson disease patients. The company's oncology pipeline consists of uPAR-targeted radiopharmaceutical candidates, including MNPR-101-Zr for diagnostic imaging, MNPR-101-Lu for radioimmunotherapy, and preclinical MNPR-101-Ac for treating advanced solid cancers. Monopar develops its pipeline through internal programs and strategic licensing, aiming to serve individuals affected by rare genetic disorders and advanced malignancies.

The company conducts clinical activities across multiple international jurisdictions, including Phase 1 clinical trials and human imaging studies in Australia, as well as an expanded access program operating in Houston, Texas. Intellectual property rights for its development pipeline encompass patent portfolios in over 30 countries, including the United States and Japan. Third-party contract manufacturing organizations handle all raw materials and clinical batch production. The company is based in the United States.

Summary of the business section of Monopar Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Monopar Therapeutics
Founded
2014
Headquarters
Wilmette, IL
Address
1000 Skokie Blvd Suite 350 60091
Phone
(847) 388-0349
Employees
22, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BPM LLP, Santa Rosa, California

Stock & identifiers

Ticker
MNPR
Exchange
Nasdaq
IPO date
Dec 19, 2019
Shares outstanding
7M, Jul 31, 2026
Public float
$155.53M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-5 reverse, Aug 13, 2024
SEC CIK
1645469
CUSIP
61023L207
ISIN
US61023L2079
FIGI
BBG00J7K8D90
Share class FIGI
BBG00J7K8DB7
LEI
549300QJFAI7L6YHKG83
EIN
32-0463781

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Chandler RobinsonChief Executive Officer, Director166,942
Pharma LLC TacticChief Executive Officer, Director4,383,299
Quan Anh VuChief Financial Officer2,655
Andrew CittadineChief Operating Officer58,054
Susan RodriguezCCSO–
Kim R. TsuchimotoDirector11,486
Raymond AndersonDirector5,373
Christopher M. StarrDirector15,053
Nicole SweenyDirector–
Arthur J. KlausnerDirector3,064,156
Lavina TalukdarDirector14,001

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.64M$17.38M$2.32M$3839–
FY2024$1.14M$2.36M$437.48K$186–
FY2023$1.78M-$166.18K$879.81K$14–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Chandler D. Robinson, MD
Chief Executive Officer and Director
$700.00K$550.00K$6.26M$2.70M$420.00K–$10.64M+829%
Quan Vu
Chief Financial Officer, Secretary, and Treasurer
$305.00K$100.00K$746.19K$795.06K$137.25K$17.82K$2.10M–
Andrew Cittadine
Chief Operating Officer
$440.00K$325.00K$2.34M$1.38M$220.00K–$4.71M+748%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 19, 2019
Offer price
$8.00
Securities offered
1,111,112
Gross proceeds
$8.89M
Exchange
Nasdaq
First trading day
Dec 19, 2019
First-day close
$26.50+231.3%
Lock-up ends (est.)
Jun 16, 2020

“The initial public offering price is $8.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 17, 2026, we had twenty-two employees, all were full-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?